A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
Haemophilia is a disorder, usually genetic, affecting mostly male individuals, in which one of the proteins needed to form blood clots (FVIII) is missing or not present in sufficient levels. In a person with haemophilia, the clotting process is much slower and the person experiences bleeding episodes that can result in serious problems and potential disability.
The current haemophilia standard of care is to maintain FVIII activity level above 1%. Sometimes, patients can develop antibodies (so called "inhibitors") against FVIII and it is no longer effective at controlling bleeds. Bleeds in these patients are currently treated using other proteins involved in the clotting process.
The purpose of this study is to investigate how effectively BAY86-6150 may stop acute bleeds in "inhibitor" patients. This study consists of two parts, A and B. The purpose of part A is to find the most effective yet tolerable out of four doses of BAY86-6150 with regard to efficacy and safety (dose-finding part). Part A is expected to last 9 - 29 months. The purpose of part B is to confirm efficacy and safety of the dose found in part A in all participating patients (confirmatory part). Part B is expected to last 12-32 months.
Approximately 60 male subjects 12 to 62 years-of-age with moderate or severe haemophilia A or B, with inhibitors to FVIII or FIX, who have had 4 or more bleeding episodes in the last 6 months, will participate in this study.
Patient's bleeds will be treated with BAY86-6150 and with a rescue medication if no response is made to BAY86-6150. Patients will attend the treatment centre at regular intervals and be required to keep an electronic diary.
Hemophilia A, Hemophilia B
Drug: eptacog alfa [activated]
|Study Design:||Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 2/3, Multicenter, Open-label Clinical Study to Assess the Safety and Efficacy of BAY86-6150 in Subjects With Hemophilia A or B With Inhibitors, Composed of 2 Parts (A & B). Part A: Sequential Cohorts of Four Dose Levels of the Modified rFVIIa BAY86-6150 Assessed in a Non-controlled Dose Response Design in Acutely Bleeding Subjects and for PK/ PD in an Intra-individual Crossover Design Compared With One Fixed Dose of Eptacog Alfa in Non-bleeding Subjects. Part B: Confirmatory Study to Further Investigate the Efficacy and Safety of BAY86-6150|
- Successful treatments of bleeding episodes. [ Time Frame: 10 hours after each bleed ]A bleed was defined as successfully treated, if no administration of rescue medication was required.
- Proportion of successful treatments of bleeding episodes on subject level. [ Time Frame: 10 hours after each bleed ]Proportion of successful treatments of bleeding episodes was calculated as number of bleeding episodes treated successfully - without rescue medication - divided by the total number of bleeding episodes on a dose level.
- Time to stop the bleed [ Time Frame: 10 hours after each bleed ]
- Number of injections needed to stop the bleeding episode. [ Time Frame: 10 hours after each bleed ]
- Effectiveness of treatment as rated by the subject's assessment (very effective, effective, partially effective, not effective). [ Time Frame: 10 hours after each bleed ]
- Participant's reported outcome as assessed by Euro QoL (EQ-5D). [ Time Frame: 14 days after last exposure to BAY86-6150 ]
- Participant's reported outcome as assessed by Brief Pain Inventory. [ Time Frame: 7 days after last exposure to BAY86-6150 ]
- Participant's reported outcome as assessed by Work Productivity and Activity Impairment Questionaire. [ Time Frame: 14 days after last exposure to BAY86-6150 ]
|Study Start Date:||June 2012|
|Study Completion Date:||March 2014|
|Primary Completion Date:||March 2014 (Final data collection date for primary outcome measure)|
|Experimental: Arm 1||
Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
|Active Comparator: Arm 2||
Drug: eptacog alfa [activated]
comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
|Experimental: Arm 3||
Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01625390
Show 61 Study Locations
|Study Director:||Bayer Study Director||Bayer|